(Q46522843)

22 December 2017

title

ERG expression in prostate cancer: the prognostic paradox (English)

1 reference

22 December 2017

4

Luc Multigner

1 reference

22 December 2017

author name string

Michael Taris

1

1 reference

22 December 2017

Jacques Irani

2

1 reference

22 December 2017

Pascal Blanchet

3

1 reference

22 December 2017

Xavier Cathelineau

5

1 reference

22 December 2017

Gaelle Fromont

6

1 reference

22 December 2017

publication date

29 August 2014

1 reference

22 December 2017

published in

The Prostate

1 reference

22 December 2017

volume

74

1 reference

22 December 2017

issue

15

1 reference

22 December 2017

page(s)

1481-1487

1 reference

22 December 2017

Epidemiology of prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Recurrent gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Antibody-based detection of ERG rearrangement-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

The prostate cancer genome: perspectives and potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

The role of SPINK1 in ETS rearrangement-negative prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

BCAR1 expression improves prediction of biochemical reccurence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22863

21 January 2018

Identifiers

DOI

10.1002/PROS.22863

1 reference

22 December 2017

PubMed ID

25175352

1 reference

22 December 2017